Your support will fund urgent
research into…
 |
PREVENTION |
More research is needed to understand why, how and when breast cancer spreads. The more we understand, the more chances we have of preventing it.
 |
DETECTION |
More research is needed to develop effective tools to predict, detect and monitor the spread of cancer. The sooner we can detect it, the better we can treat it.
 |
TARGETED TREATMENTS |
More research is needed for personalised treatments for metastatic breast cancer. The more targeted the treatment strategy, the better the outcome.
The funds you raise are vital. The more you raise, the closer we get to Zero Deaths from breast cancer.
Could support researchers in the development of a new combination therapy that is more potent against metastatic breast cancer, while reducing harmful side-effects and heart damage.
Could support researchers to develop world-class diagnostic and imaging tools to see exactly where breast cancer has spread, as early as possible.
Could support researchers to develop a simple, non-invasive blood test to predict, detect and monitor the return and spread of breast cancer. This could lift the cloud of fear that so many breast cancer survivors live under.
WHERE YOUR MONEY GOES
When you support the National Breast Cancer Foundation (NBCF), you’re supporting targeted breast cancer research – research that is selected for its potential to reap tangible, game-changing results. NBCF has a number of groundbreaking research projects focusing on the prevention, detection and treatment of metastatic breast cancer. Here are just a few. With your help, we can fund more.
 |
ASSOCIATE PROFESSOR ALEXANDER SWARBRICKGarvan Institute of Medical Research NBCF-funded researcher Associate Professor Alexander Swarbrick is using cutting-edge technologies to study the genetics of cancer cells of women with triple negative breast cancer. He’s using ‘single cell genomics’ to analyse samples collected during chemotherapy as well as during metastatic stages of the disease. This exciting research may not only uncover the fundamental mechanisms controlling the response to chemotherapy, but may also provide remarkable new opportunities for predictive tests and drug targets for chemo-resistant triple negative breast cancer. |
 |
DR SHARISSA LATHAMGarvan Institute of Medical Research NBCF-funded researcher Dr Sharissa Latham aims to develop a new drug, called K12, into the first-ever clinically and commercially viable drug to inhibit the growth of TNBC cancer cells that have already metastasised. The drug works by targeting a protein needed for the metastatic growth of TNBC, called oncogenic (cancer-causing) JNK. If successful, the development of this drug would have a major impact on the treatment and outcomes of patients with TNBC. |
 |
DR DANIEL RODENGarvan Institute of Medical Research Dr Daniel Roden's project aims to better characterise the individual cells in hard-to-treat tumours, and how these cells interact with each other to better understand why some tumours respond to treatment and others do not. By investigating tumour composition in more detail, individual communities of cell types that are associated with poor outcome will be identified. This will allow more precise assessment of prognosis for breast cancer patients and may also allow more efficient targeted treatment options. |
